CervoMed Inc. reports clinical-stage biotechnology developments centered on neflamapimod, an oral small-molecule drug candidate for age-related brain disorders. Company news most often covers dementia with Lewy bodies, the Phase 2b RewinD-LB trial, biomarker and MRI analyses, pharmacokinetic work, formulation and dosing disclosures, and regulatory interactions tied to later-stage development.
Updates also include financial results, grant revenue trends, investor conference presentations, shareholder voting matters, governance items, and capital-structure disclosures. CervoMed has also reported neflamapimod's inclusion in the UK EXPERTS-ALS platform for amyotrophic lateral sclerosis research.
CervoMed (NASDAQ: CRVO) will feature five scientific presentations at the Alzheimer’s Association International Conference (AAIC) 2026 in London, July 12-15.
Four presentations focus on neflamapimod in dementia with Lewy bodies (DLB), covering disease progression, MRI biomarkers, exposure-response, and 80 mg BID dosing, plus a new DLB goal attainment tool.
CervoMed (NASDAQ: CRVO) closed a $10 million registered direct offering of common stock priced at-the-market under Nasdaq rules. The company sold 2,500,000 shares at $4.00 per share, with H.C. Wainwright & Co. as exclusive placement agent.
CervoMed plans to use net proceeds for working capital and general corporate purposes. The securities were issued under an effective Form S-3 shelf registration statement, with a final prospectus supplement filed with the SEC.
CervoMed (NASDAQ: CRVO) entered definitive agreements for a registered direct offering of 2,500,000 common shares at $4.00 per share, priced at-the-market under Nasdaq rules.
Gross proceeds are expected to be $10 million, closing around June 22, 2026, with funds for working capital and general corporate purposes.
CervoMed (NASDAQ: CRVO) received a USPTO notice of allowance for a new U.S. patent covering use of its drug candidate neflamapimod to treat dementia with Lewy bodies (DLB) in patients without substantial Alzheimer’s-like tau pathology, or “pure DLB”.
The patent, based on biomarker-defined patients using plasma pTau or brain imaging, is expected to provide intellectual property protection into 2042, supporting CervoMed’s pure DLB treatment strategy. There are currently no approved DLB treatments in the U.S. or EU.
CervoMed (NASDAQ: CRVO), a clinical-stage biotech focused on age-related brain disorders, will join the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit.
Management will host a virtual fireside chat and one-on-one investor meetings on Monday, June 15, 2026, with a webcast available via the company’s investor section.
CervoMed (NASDAQ:CRVO) entered a definitive securities purchase agreement for a private placement expected to raise approximately $10.5 million upfront.
According to CervoMed, proceeds should extend its cash runway into Q2 2027 and support strategic partnering to advance neflamapimod into Phase 3 for dementia with Lewy bodies and other Phase 2a programs.
CervoMed (NASDAQ: CRVO) reported Q1 2026 results and clinical progress for neflamapimod across several neurodegenerative indications.
Key points include finalized Phase 3 DLB trial design, new MRI and biomarker data, a new European patent to 2040, $12.9M cash and a $8.0M quarterly net loss.
CervoMed (NASDAQ: CRVO) reported MRI analyses from the RewinD-LB Phase 2b trial showing right basal forebrain (BF) volume increased with neflamapimod (+10.9 mm3, +3.5%) versus placebo decline (–13.3 mm3, –4.2%) at week 16 (p=0.022; p=0.028 percent change). Functional connectivity (right BF→DMN) rose 46% during the extension (p=0.014) and correlated with CDR-SB improvement (p=0.027, r2=0.43). Results were blinded, validated against autopsy pathology, and CervoMed plans a Phase 3 trial in DLB subject to financing.
CervoMed (NASDAQ: CRVO) provided a clinical update on neflamapimod at the 2026 Lewy Body Dementia Association Annual Meeting on April 7, 2026. The company reported finalized Phase 3 trial design and alignment with global regulators, plus new Phase 2b MRI analyses suggesting reduced basal forebrain atrophy and altered functional connectivity.
Additional MRI data will be presented at the 2026 American Academy of Neurology meeting on April 22, 2026. The company also highlighted plasma GFAP as a blood biomarker that correlated with clinical outcome (CDR‑SB) and showed responsiveness to treatment.
CervoMed (NASDAQ: CRVO) presented Phase 2b RewinD-LB analyses at AD/PD 2026 showing greater clinical benefit from neflamapimod in DLB patients with lower plasma pTau181 (indicative of absent AD co-pathology).
Within-participant comparisons show CDR-SB differences up to -1.11 (p=0.005) in the lowest pTau181 subgroup, a planned Phase 3 enrichment cutoff of <21 pg/mL, and a pharmacologic activity threshold of Ctrough 4 ng/mL.